News | Renal Denervation | June 26, 2020

Simplicity Renal Denervation Lowered Blood Pressure Out to 3 Years

Regardless of the number of anti-hypertensive medications, majority of patients with highest BP showed significant drops at three years

The Medtronic Symplicity Spyral renal denervation catheter in the renal artery, showing how its four electrodes contact the vessel wall for a single RF energy delivery procedure. By ablating the vessel walls, it props the vessel in a fully open position, allowing the kidneys to better filter the blood and remove excess water in hypertension patients. RDN

The Medtronic Symplicity Spyral renal denervation catheter in the renal artery, showing how its four electrodes contact the vessel wall for a single RF energy delivery procedure. By ablating the vessel walls, it props the vessel in a fully open position, allowing the kidneys to better filter the blood and remove excess water in hypertension patients.

June 26, 2020 – New data from the Global SYMPLICITY Registry (GSR) showed that renal denervation (RDN) with the Medtronic Symplicity Renal Denervation System significantly reduced blood pressure (BP) in uncontrolled hypertension patients out to three years independent of anti-hypertension medication burden. The data were presented virtually as part of the PCR e-Course 2020 this week. 

The study showed RDN led to significant and clinically meaningful reductions in hypertension that were sustained out to three years post-procedure (17 mmHg OSBP (office systolic blood pressure)), with more patients achieving BP below 140 mmHg, while those at very high BP levels experiencing drops into lower risk BP ranges. The number of patients at the very highest BP level – greater than 180 mmHg systolic at baseline – dropped by two-thirds at three years. Additionally, the number of patients who had reported office systolic BP less than 140 mmHg – a more controlled level of BP – increased from 13 percent at baseline to 39 percent at three years. The BP drops occurred while patients were prescribed an average of four or more anti-hypertensive medications, which remained unchanged over three years. The absence of increase in medications suggest that RDN’s effect was independent of anti-hypertensive medication burden. RDN continued to show a strong safety profile at three years with an incidence of renal artery stenosis of 0.3 percent, which is within the expected range for patients with hypertension not undergoing denervation.

“In the largest real-world study of patients receiving renal denervation, we are seeing significant and clinically meaningful reductions in both office and 24-hr blood pressure sustained out to three years post-procedure, which demonstrates the durability of RDN,” said Felix Mahfoud, M.D., cardiologist at Saarland University Medical Center in Homburg, Germany, who presented the data during the meeting. “These data reinforce that RDN is a viable, complementary option with positive effects on hypertensive patients without requiring an increase in medication burden over time.”

The Global SYMPLICITY Registry is the largest study documenting the long-term safety and effectiveness of the Medtronic renal denervation systems in a real-world setting in patients with uncontrolled hypertension. To date, the registry has enrolled more than 2,860 patients treated with RDN and includes three-year follow-up for more than 2,500 patients. The data presented at PCR closely mirror a recent manuscript of GSR data published in JACC, which reported that RDN showed lasting results in a variety of high-risk patients, including those with diabetes, chronic kidney disease (CKD), isolated systolic hypertension (ISH), or resistant hypertension.

"Following the positive SPYRAL HTN-OFF MED Pivotal data presented at ACC, these new data provide additional evidence on the safety and efficacy of renal denervation to help manage uncontrolled hypertension, with study patients experiencing meaningful blood pressure reductions out to several years,” said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. "As the body of clinical evidence supporting renal denervation grows, we are encouraged by the outcomes observed in both controlled clinical trials and real-world practice.” 

Hypertension is the single largest contributor to cardiovascular death; it dramatically increases risk of heart attack, stroke, heart failure, and kidney failure. The annual direct costs of hypertension are estimated at $500 billion worldwide. It is estimated that almost 20 percent of patients are completely non-adherent to oral medications while nearly half are partially non-adherent, highlighting the need for alternative treatment options.

In addition to the Global SYMPLICITY Registry, the Medtronic SPYRAL HTN Global Clinical Program includes the SPYRAL HTN-OFF MED PIVOTAL and SPYRAL HTN-ON MED Trials, both prospectively powered, randomized, sham-controlled studies evaluating patients with uncontrolled blood pressure in the absence and presence of prescribed anti-hypertensive medications respectively. Approved for commercial use in more than 50 countries around the world, the Symplicity Spyral system is limited to investigational use in the United States.

For more information: www.medtronic.com

 

Related Renal Denervation Content:

Renal Denervation Shows Significant Drop in Hypertension

Renal Artery Denervation and Catheter Ablation Increased Freedom From Atrial Fibrillation

Medtronic Study Evaluating Combination of Pulmonary Vein Isolation, Renal Denervation for Atrial Fibrillation

VIDEO: New Approaches to Denervation Therapy 

Renal Artery Denervation and Catheter Ablation Increased Freedom From Atrial Fibrillation

VIDEO: Device Therapies to Treat Hypertension

SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation

Medtronic Announces Spyral HTN Global Clinical Trial Program for Renal Denervation

Medtronic Randomizes First Patients in Symplicity HTN-4

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo